Skip to content

Observation on Efficacy and Safety of Dexmedetomidine NasalSprayAssisted with Ciprofol in EndoscopicPolypectomy

Observation on Efficacy and Safety of Dexmedetomidine NasalSprayAssisted with Ciprofol in EndoscopicPolypectomy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500115077
Enrollment
Unknown
Registered
2025-12-22
Start date
2025-12-23
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal polyps

Interventions

Group A:Use dexmedetomidine nasal spray before anesthesia.
Group B:Use saline nasal spray before anesthesia

Sponsors

Jinjiang Hospital (Shanghai Sixth People's Hospital Fujian Branch)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1 Age: 45-75 years old, gender not limited; 2 American Society of Anesthesiologists (ASA) grade I - II; 3 Polyp resection under gastroscopy and colonoscopy is proposed; 4 No contraindications for endoscopic examination; 5 Pre-examination blood oxygen saturation (SpO2) >= 90%; 6 Those who have no allergic reactions to the drugs used in this study.

Exclusion criteria

Exclusion criteria: 1 Have a history of allergy or contraindications to the drugs involved in the study (such as dexmedetomidine, cyclopofol, etc.); 2 Those accompanied by bradycardia; 3 There are communication barriers or mental illnesses; 4 Severe respiratory, circulatory, liver and kidney dysfunction; 5 Severe nasal congestion, nasal diseases or history of nasal surgery, use of nasal spray; 6 Positive assessment of difficult airways or obstructive sleep apnea syndrome (OSAHS); 7 Long-term use of sedative and analgesic drugs, psychotropic drugs or a history of substance abuse; 8 Poorly controlled hypertension (resting blood pressure >180/100 mmHg) or a history of severe cardiovascular disease.

Design outcomes

Primary

MeasureTime frame
respiratory depression;

Secondary

MeasureTime frame
Blood pressure;Heart rate;The initial dose of Ciprofol;body movement;recovery time;Number of supplemental doses;Additional total amount;

Countries

China

Contacts

Public ContactYushanSu

Jinjiang Hospital (Shanghai Sixth People's Hospital Fujian Branch)

874016619@qq.com+86 159 6074 1118

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026